Ipca Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Pranay Godha

İcra Kurulu Başkanı

₹65.2m

Toplam tazminat

CEO maaş yüzdesi	25.7%
CEO görev süresi	1.7yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	9.5yrs

Son yönetim güncellemeleri

Recent updates

Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price

Dec 20

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Nov 17

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30

CEO Tazminat Analizi

Pranay Godha'un ücretlendirmesi Ipca Laboratories'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹7b
Jun 30 2024	n/a	n/a	₹6b
Mar 31 2024	₹65m	₹17m	₹5b
Dec 31 2023	n/a	n/a	₹6b
Sep 30 2023	n/a	n/a	₹5b
Jun 30 2023	n/a	n/a	₹5b
Mar 31 2023	₹51m	₹13m	₹5b
Dec 31 2022	n/a	n/a	₹5b
Sep 30 2022	n/a	n/a	₹6b
Jun 30 2022	n/a	n/a	₹7b
Mar 31 2022	₹46m	₹12m	₹9b
Dec 31 2021	n/a	n/a	₹9b
Sep 30 2021	n/a	n/a	₹10b
Jun 30 2021	n/a	n/a	₹10b
Mar 31 2021	₹32m	₹8m	₹11b
Dec 31 2020	n/a	n/a	₹11b
Sep 30 2020	n/a	n/a	₹10b
Jun 30 2020	n/a	n/a	₹9b
Mar 31 2020	₹33m	₹8m	₹6b
Dec 31 2019	n/a	n/a	₹6b
Sep 30 2019	n/a	n/a	₹6b
Jun 30 2019	n/a	n/a	₹5b
Mar 31 2019	₹29m	₹8m	₹4b
Mar 31 2018	₹25m	₹7m	₹2b

Tazminat ve Piyasa: Pranay 'ın toplam tazminatı ($USD 765.06K ) Indian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 595.83K ).

Tazminat ve Kazançlar: Pranay 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Pranay Godha (52 yo)

1.7yrs

Görev süresi

₹65,228,222

Tazminat

Mr. Pranay Premchand Godha served as the President of APIs & Generics at Ipca Laboratories Limited and joined it on April 16, 2003. He serves as Non-Executive, Non-Independent Director at Unichem Laborator...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Premchand Godha	Executive Chairman	49.2yrs	₹123.00m	2.29% ₹ 9.3b
Pranay Godha	CEO, MD & Executive Director	16.1yrs	₹65.23m	0.67% ₹ 2.7b
Ajit Kumar Jain	CFO, MD & Executive Director	30.3yrs	₹84.44m	0.017% ₹ 66.9m
Prashant Godha	Executive Director	13.3yrs	₹69.76m	0.62% ₹ 2.5b
Narendra Mairpady	Additional Independent Director	2.2yrs	₹1.25m	Veri yok
Kamal Seth	Lead Independent Director	5.8yrs	₹1.60m	0.00067% ₹ 2.7m
Swati Patankar	Independent Director	less than a year	₹250.00k	Veri yok
Vivek Shiralkar	Independent Director	less than a year	Veri yok	0.000080% ₹ 323.6k

9.5yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IPCALAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/26 07:46
Gün Sonu Hisse Fiyatı	2024/12/26 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Ipca Laboratories Limited 46 Bu analistlerden 19, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Aditya Khemka	Ambit Capital
null null	Anand Rathi Shares and Stock Brokers Limited
Sanjeev Chiniwar	Anand Rathi Shares and Stock Brokers Limited

Ipca Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024

Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent Director

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Less than half of directors are independent

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

Recent updates

Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price

Price target increased by 7.8% to ₹1,564

Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Dividend of ₹2.00 announced

Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Price target increased by 8.6% to ₹1,320

Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent Director

Upcoming dividend of ₹2.00 per share

Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Less than half of directors are independent

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Ipca Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

Price target increased by 9.1% to ₹1,097

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

CFO, MD & Executive Director recently sold ₹22m worth of stock

Price target increased by 9.7% to ₹987

Upcoming dividend of ₹2.00 per share at 0.2% yield

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023

Price target decreased by 7.1% to ₹858

Investor sentiment deteriorates as stock falls 15%

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates fall by 21%

Third quarter 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022

Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Insider recently sold ₹1.7m worth of stock

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022

Now 20% undervalued

Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent Director

Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Now 20% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022

Now 20% undervalued after recent price drop

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Now 20% undervalued after recent price drop

Price target decreased to ₹1,067

Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Full year 2022 earnings: EPS misses analyst expectations

Insufficient new directors